Turn Biotechnologies

mRNA epigenetic reprogramming · Skin, immune, ocular aging

PreclinicalPartial Epigenetic Reprogramming

Mechanism

mRNA epigenetic reprogramming

Intervention class

mRNA

Indication

Skin, immune, ocular aging

Stage

Preclinical

Evidence

animal

Funding

VC-backed

Backers

Various

Overview

Transient mRNA delivery of reprogramming factors ('ERA') to rejuvenate cells without permanent genetic change. Lead programs in dermatology and immune aging.

Technology

Turn Biotechnologies works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.

Read the Partial Epigenetic Reprogramming brief →

Related companies

Altos Labs

Partial epigenetic reprogramming

Retro Biosciences

Reprogramming, autophagy, plasma factors

Life Biosciences

Partial reprogramming (OSK via AAV)

NewLimit

Epigenetic reprogramming (factor discovery)

Rejuvenate Bio

Gene therapy (FGF21, sTGFβR2, klotho); reprogramming

Shift Bioscience

Reprogramming w/o dedifferentiation

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.